Top Sustained Release Excipients Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Sustained Release Excipients Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Sustained Release Excipients industry players.

Sustained Release Excipients Market Competitive Landscape

The competitive landscape in the market is defined by the several companies engaged in fierce competition to gain a competitive advantage by focusing on R&D to develop new excipient formulations and delivery systems. Market players are employing strategic partnerships and acquisitions to expand their reach.

As regulatory requirements and consumer tastes evolve to align with sustainable goals, the market sees a rising demand in green and eco-friendly excipient solutions, which market participants intend to meet. This competitive environment drives innovation and product differentiation, which is a win for healthcare stakeholders as it places heavy importance on drug delivery technology developments.

Top Player’s Company Profiles

  • Allergan PLC (Ireland)
  • AstraZeneca (UK)
  • GlaxoSmithKline PLC (UK)
  • Mylan NV (US)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • Salix Pharmaceuticals (US)
  • Roche Holdings AG (Switzerland)
  • Sanofi (France)
  • Johnson & Johnson (US)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • AbbVie Inc. (US)
  • Bristol-Myers Squibb (US)
  • Gilead Sciences, Inc. (US)
  • Bayer AG (Germany)
  • Takeda Pharmaceutical Company Limited (Japan)
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Sustained Release Excipients Market size was valued at USD 1.73 Billion in 2024 and is poised to grow from USD 1.87 Billion in 2025 to USD 3.49 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026–2033).

The competitive landscape in the market is defined by the several companies engaged in fierce competition to gain a competitive advantage by focusing on R&D to develop new excipient formulations and delivery systems. Market players are employing strategic partnerships and acquisitions to expand their reach. 'International Flavors & Fragrances Inc. (United States)', 'Evonik Industries AG (Germany) ', 'BASF SE (Germany) ', 'Kerry Group Plc (Ireland) ', 'Roquette Freres (France) ', 'Merck KGaA (Germany) ', 'Associated British Foods Plc (United Kingdom) ', 'ADM (United States) ', 'Wacker Chemie AG (Germany) ', 'Croda International Plc (United Kingdom) ', 'Gattefossé (France) ', 'Colorcon Inc. (United States) ', 'AstraZeneca PLC (United Kingdom) ', 'GlaxoSmithKline PLC (United Kingdom) ', 'Mayne Pharma Group Limited (Australia) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Pfizer Inc. (United States) ', 'Novartis AG (Switzerland)'

The constantly aging population is driving this market as the global demographic landscape shifts to an older age population, propelling demand for healthcare products and pharmaceuticals. Sustained release excipients provide benefits like extended drug release to improve compliance and manage chronic conditions effectively, cementing its importance producing medications that cater to the specific needs of elderly patients. As healthcare providers target the healthcare challenges associated with an aging population, this demographic shift will drive steady demand for sustained release excipients in the pharmaceutical sector.

Increased Focus on Personalized Medicine: The growing emphasis on personalized medicine is trending in the pharmaceutical industry, including the sustained release excipients market. Advances in biomarker identification and genomics are targeting the development of medications designed according to individual patient profiles. Sustained excipients enable precise dosing and prompt timing of optimized release in therapeutic outcomes while minimizing side effects, highlighting its significance in formulation of these personalized drug delivery systems. This trend is in line with the shift towards patient-centric healthcare, driving innovation in excipient formulations and technologies.

North America dominates the market due to its thriving pharmaceutical industry, enriched by rigorous R&D, making it a global centre for drug formulation. The adoption of sustained release excipients is being driven further by a strong emphasis on patient-centric healthcare and rigid regulatory standards placed to guarantee drug efficiency and safety. The region's position in the market is strengthened by its substantial healthcare expenditure and large presence of renowned pharmaceutical companies.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Pharmaceutical Excipients Market
Buy Now GET FREE SAMPLE
Release Coatings Market
Buy Now GET FREE SAMPLE
Controlled Release Drug Delivery Market
Buy Now GET FREE SAMPLE
Excipients Market
Buy Now GET FREE SAMPLE
Release Liners Market
Buy Now GET FREE SAMPLE
Biopharmaceuticals Excipients Market
Buy Now GET FREE SAMPLE
Controlled Release Fertilizers Market
Buy Now GET FREE SAMPLE
Mold Release Agents Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Sustained Release Excipients Market
Sustained Release Excipients Market

Report ID: SQMIG35I2231

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE